Article Information
- Received April 20, 2017
- Revision received September 10, 2017
- Accepted September 16, 2017
- First published September 26, 2017.
- Version of record published October 25, 2017.
Author Information
- Mari Sepp1,
- Hanna Vihma1,*,
- Kaja Nurm1,*,
- Mari Urb1,*,
- Stephanie Cerceo Page2,
- Kaisa Roots1,
- Anu Hark1,
- Brady J. Maher2,3,4,
- Priit Pruunsild1, and
- Tõnis Timmusk1
- 1Department of Chemistry and Biotechnology, Tallinn University of Technology, 12618 Tallinn, Estonia,
- 2Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, Maryland 21205, and
- 3Department of Psychiatry and Behavioral Sciences and
- 4Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, Maryland 21205
Author contributions
Author contributions: M.S., B.J.M., and T.T. designed research; M.S., H.V., K.N., M.U., S.C.P., K.R., A.H., and P.P. performed research; M.S., H.V., K.N., M.U., S.C.P., K.R., A.H., B.J.M., P.P., and T.T. analyzed data; M.S., P.P., and T.T. wrote the paper.
↵*H.V., K.N., and M.U. contributed equally to this work.
Disclosures
- Received April 20, 2017.
- Revision received September 10, 2017.
- Accepted September 16, 2017.
This work was supported by Estonian Research Council (institutional research funding IUT19-18 Grants 7257 and 8844), the National R&D program “Health” (Grant AR12098), the European Union through the European Regional Development Fund (Project No. 2014-2020.4.01.15-0012) and H2020-MSCA-RISE-2016 (EU734791), the Estonian Academy of Sciences, and the Pitt Hopkins Research Foundation and Million Dollar Bike Ride Pilot Grant Program for Rare Disease Research at UPenn Orphan Disease Center (Grants MDBR-16-122-PHP and MDBR-17-127-Pitt Hopkins). B.J.M. was supported by the Lieber Institute of the National Institutes of Health (Grant R56MH104593), the National Institutes of Health (Grant R01MH110487), a NARSAD Young Investigator Award, and a Pitt Hopkins Research Foundation Award. We thank Indrek Koppel for constructive discussions and critical reading of the manuscript; Epp Väli and Maila Rähn for technical assistance; Buket Basmanav for sharing data about TCF4 mutations in szhizophrenia patients; and Hilmar Bading for pRV1, pH21, pFdelta6, and rAAV-U6-shRNA-mCherry constructs.
The authors declare no competing financial interests.
- Correspondence should be addressed to either Mari Sepp or Tõnis Timmusk, Department of Chemistry and Biotechnology, Tallinn University of Technology, Akadeemia tee 15, 12618 Tallinn, Estonia. mari.sepp{at}ttu.ee or tonis.timmusk{at}ttu.ee
Other Version
- previous version (September 26, 2017).
- You are viewing the most recent version of this article.
Online Impact